Supplementary Explanation of the Mechanism of Action
- Receptor Blocking Property
RU58841 not only inhibits 5α-reductase but also directly binds to the androgen receptor (AR), competitively blocking the binding of DHT to hair follicle receptors, and inhibiting the attack of androgens on hair follicles through a dual pathway. - Differences from Finasteride
- Finasteride (oral) selectively inhibits type II 5α-reductase, reducing the production of DHT;
- RU58841 inhibits both type I and type II 5α-reductases simultaneously and exerts its effect through the receptor blocking mechanism. Theoretically, it can inhibit the local DHT in the scalp more thoroughly.
-
Main Effects
- Reducing Hair Loss
By reducing the local DHT concentration in the scalp, it delays the process of hair follicle miniaturization. Most users will experience a significant reduction in hair loss after 3 to 6 months. - Promoting Hair Growth
New hair growth can be observed in about 30% to 40% of users (especially in the crown area), and the hair density is improved. - Improving Hair Quality
The diameter of new hair increases, its toughness is enhanced, and it gradually restores a healthy state.
Suitable Population
- Early to mid-stage male pattern baldness: It has the best effect when the hair follicles are not fully closed.
- Those who are intolerant to finasteride or worried about its side effects: RU58841 is a topical preparation with low systemic absorption, and the risk of side effects related to sexual function is significantly lower than that of oral medications (about 2% for finasteride).
Usage Method
- Topical application: Apply an appropriate amount of solution or gel evenly to the scalp in the hair loss area 1 to 2 times a day, and massage until absorbed.
- Treatment course requirement: It is necessary to use it continuously for more than 6 months to evaluate the effect. Hair loss may recur after stopping the medication.
Precautions
- Side Effects
- Common: Slight scalp itching and erythema (with an incidence rate of about 5% to 8%), which usually subsides within 2 weeks.
- Long-term safety: Current European clinical data show that no systemic side effects have been observed after continuous use for 2 years, but the long-term impact on sexual function still needs to be verified by large-scale sample studies.
- Individual Differences
The effect is affected by the severity of hair loss, the state of the hair follicles, and the compliance with the medication. About 15% of users may not have obvious improvement.
Comparison with Other Drugs
| Drug | Advantages | Limitations |
|---|---|---|
| Finasteride | Definite curative effect (with an effective rate of about 90%) | Oral administration may cause sexual dysfunction (2%) |
| Minoxidil | No hormonal dependence, wide range of application | Long-term use may lead to dry scalp |
| RU58841 | Safe local action, no systemic side effects | The curative effect is weaker than that of finasteride (with an effective rate of about 60%) |
This one is more commonly sold on the market, which is for reference only.
Conclusion
As a topical dual-target drug, RU58841 provides a safer treatment option for androgenetic alopecia, especially for patients who are sensitive to oral medications or in the early stage of hair loss. It is recommended to formulate a treatment plan under the guidance of a professional physician, combined with the results of hair follicle testing.